US · Healthcare · Biotechnology
EPS came in at 1.83 against a street estimate of 1.42 — a beat of 28.9%.
Analysts rate Krystal Biotech Inc a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $384.43.
| Fund | Stake |
|---|---|
| FMR Inc | 14.84% |
| BlackRock Inc | 13.37% |
| venBio Select Advisor LLC | 9.80% |
| Vanguard Portfolio Management, LLC | 4.94% |
| State Street Corp | 4.46% |
| Vanguard Capital Management, LLC | 3.95% |
| Soleus Capital Management, L.P. | 3.91% |
| Capital World Investors | 2.80% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-21 |
| Shareholder vote results · Q2 2026 | 2026-05-20 |
| Current report · Q2 2026 | 2026-05-04 |
| Quarterly report · Q1 2026 | 2026-05-04 |
| Proxy statement · Q2 2026 | 2026-04-03 |
| Results announced · Q1 2026 | 2026-02-17 |
| Annual report FY2025 | 2026-02-17 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| Q4 2025 and full year revenue guidance provided; 2026 expense guidance issued Krystal Biotech announced preliminary 2025 financial results ahead of presenting at the J.P. Morgan Healthcare Conference. The company's lead product, VYJUVEK, generated strong revenue: $106 | 2026-01-12 |
| VYJUVEK commercial launch in Japan following NHI drug price listing Krystal Biotech announced that its Japanese subsidiary began commercial sales of VYJUVEK (beremagene geperpavec) on October 22, 2025, following approval for Japan's National Health Insurance | 2025-10-22 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Krystal Biotech Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.